646 DOES ADJUVANT CHEMOTHERAPY TYPE DIFFER FOR UPPER URINARY TRACT TRANSITIONAL CELL CARCINOMA SURVIVAL?

Abstract

You have accessJournal of UrologyUrothelial Cancer: Upper Tract Tumors1 Apr 2012646 DOES ADJUVANT CHEMOTHERAPY TYPE DIFFER FOR UPPER URINARY TRACT TRANSITIONAL CELL CARCINOMA SURVIVAL? Artan Koni, Bulent Akdogan, Halil Kiziloz, Irfan Donmez, Cenk Yucel Bilen, and Haluk Ozen Artan KoniArtan Koni Ankara, Turkey More articles by this author , Bulent AkdoganBulent Akdogan Ankara, Turkey More articles by this author , Halil KizilozHalil Kiziloz Ankara, Turkey More articles by this author , Irfan DonmezIrfan Donmez Ankara, Turkey More articles by this author , Cenk Yucel BilenCenk Yucel Bilen Ankara, Turkey More articles by this author , and Haluk OzenHaluk Ozen Ankara, Turkey More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.02.725AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To analyze cancer specific survival for upper urinary tract transitional cell carcinoma (UUTTCC) patients treated with CMV or gemcitabine-cisplatin (G/C) based regimens. METHODS Data of 110 patients who underwent nephroureterectomy for UUTTCC in the last 20 years were reviewed retrospectively. 21 patients who were given adjuvant chemotherapy for local or systemic recurrences were included in survival analyses. CMV (cisplatine, methotrexate and vinblastine) and G/C (gemcitabine and cisplatine) regimens were administered to 8 and 13 patients, respectively. RESULTS Mean age and mean follow-up of all patients was 60.83 years and 57.42 months, respectively. Mean age and mean follow-up of patients receiving adjuvant chemotherapy was 59.76 years and 29.43 months, respectively. Mean chemotherapy cycles in CMV and G/C groups were 3.9 and 5.6, respectively. No difference in demographic and clinical variables was detected between CMV and G/C patients. Smoking history was more often detected in CMV arm (p=0.017). G/C was better tolerated than CMV. Toxicity parameters were similar, although more neutropenia was detected in CMV arm. Two-years cancer specific survival for CMV and G/C was similar in both groups (50% vs 53.7%, respectively). Mean survival was 36.7±6.7 and 38.5±10.5 months, respectively. Patients with extrapulmonary metastasis lived shorter than the ones with pulmonary metastasis only; mean survival was 15.6±3.9 and 67.7±10.1 months, respectively (p=0.000). CONCLUSIONS G/C is better tolerated than CMV regiment. Extrapulmonary metastasis predicts worse survival in UUTTCC patients. © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 187Issue 4SApril 2012Page: e263 Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.MetricsAuthor Information Artan Koni Ankara, Turkey More articles by this author Bulent Akdogan Ankara, Turkey More articles by this author Halil Kiziloz Ankara, Turkey More articles by this author Irfan Donmez Ankara, Turkey More articles by this author Cenk Yucel Bilen Ankara, Turkey More articles by this author Haluk Ozen Ankara, Turkey More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...